Zimmer Biomet Cleaned House After FDA Inspection at Warsaw Plant

Zimmer Biomet has undertaken personnel changes in its plant in Warsaw, Ind., after an FDA inspection last year uncovered multiple violations. Five operations and quality executives have been dismissed in an effort to improve the conditions at the plant.

The company responded to the FDA’s inspection by acknowledging that there were unprecedented difficulties after their $14 billion merger of Zimmer and Biomet. They had begun conducting internal audits and uncovered issues in 2016 before the FDA’s inspection.

Their changes include replacing the senior vice president of global operations and logistics; the vice president of quality assurance at all of Zimmer-Biomet’s Warsaw sites; the quality assurance director for the Warsaw North Campus; the compliance director of the Biomet network; and the QA director for post-market surveillance and complaint handling for the Warsaw site.